Mapping Disease Pathways for Biliary Atresia (BA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03273049|
Recruitment Status : Recruiting
First Posted : September 6, 2017
Last Update Posted : January 6, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease|
Characterized by failure to drain bile from the liver due to atretic extrahepatic bile ducts, BA is corrected in less than half of all affected children with surgical reconstruction. The remainder progress to cirrhosis and require liver transplantation. Because bile duct loss can be accompanied by other birth defects such as laterality defects of the gut and cardiovascular systems, the disease has been categorized into the more common 'isolated' variety presumably due to a perinatal viral cholangitis, and the 'syndromic' variety, due to genetic factors. Mechanistic differences implied by this categorization have not been demonstrated conclusively. In contrast, three susceptibility genes identified in predominantly 'isolated" BA cases, and the presence of abnormal cilia which are known to predispose to laterality defects, in both isolated and syndromic forms of BA suggest that in addition to environmental influences, genetic susceptibility is important in both forms of BA. This view is reinforced by our preliminary work which shows that knockdown of a novel BA susceptibility gene causes both biliary dysgenesis and laterality defects in animal models. This finding also suggests that common birth defects affecting the liver and other organs may originate from defects in the same genes. The project will combine candidate gene identification and replication with human DNA samples from 1100 BA subjects and their biological parents or siblings, if available, with validation using corresponding human BA liver tissue and zebrafish knockdown models.
The project outcome will consist of pathways comprising multiple susceptibility genes involved in morphogenesis of the liver and other organs, which explain the complex phenotype of BA. The project will use the experimental and bioinformatics capabilities of the Universities of Pittsburgh and California (at San Diego) to analyze data and study human samples from the participating centers. Four of the world's largest pediatric liver transplant centers, the Children's Hospitals of Pittsburgh (CHP), King's College Hospital (KCH), London, UK, Birmingham Children's Hospital, UK (BCH), and the Hospital Sirio Libanes (HSL), Sao Paulo, Brazil will enroll biliary atresia subjects and their biological parents and/or siblings, if available.
Information developed in this project will be the basis for designing novel management strategies to reduce the societal impact of this rare childhood disease.
|Study Type :||Observational|
|Estimated Enrollment :||1100 participants|
|Official Title:||Coordinating Center- Mapping Disease Pathways for Biliary Atresia|
|Actual Study Start Date :||July 21, 2016|
|Estimated Primary Completion Date :||December 21, 2024|
|Estimated Study Completion Date :||July 21, 2026|
- Genomic pathways of BA [ Time Frame: up to two years ]Main project outcome will consist of pathways comprising multiple susceptibility genes involved in morphogenesis of the liver and other organs, which explain the complex phenotype of BA.
- Predisposition of BA [ Time Frame: upwards of four years to achieve this outcome measure ]determine whether candidate genes and related pathways which predispose to BA, also predispose to laterality defects affecting the liver and other organs.
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||Child, Adult, Older Adult|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- living individuals who were diagnosed with Biliary Atresia and received or are about to receive a liver transplant from multiple participating centers (Children's Hospital of Pittsburgh, Kings College Hospital, Children's Hospital of Birmingham, and Hospital Sírio-Libanês).
- No child participant in the care of the state will be enrolled, nor will patients in the care of temporary or informal guardians be enrolled
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03273049
|Contact: Morgan L Paul, BSN||4126928472||Morgan.Paul2@upmc.edu|
|Contact: Daniel Pieratt, MPAemail@example.com|
|United States, Pennsylvania|
|UPMC Children's Hospital of Pittsburgh||Recruiting|
|Pittsburgh, Pennsylvania, United States, 15224|
|Contact: Morgan L Paul, BSN 412-692-8472 Morgan.Paul2@upmc.edu|
|Contact: Daniel Pieratt, MPA 4126926692 firstname.lastname@example.org|
|Principal Investigator: Rakesh Sindhi, MD|
|Responsible Party:||Rakesh Sindhi, Rakesh Sindhi, MD, Professor of Surgery, University of Pittsburgh|
|Other Study ID Numbers:||
1R01DK109365-01A1 ( U.S. NIH Grant/Contract )
|First Posted:||September 6, 2017 Key Record Dates|
|Last Update Posted:||January 6, 2023|
|Last Verified:||January 2023|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases
Digestive System Abnormalities